z-logo
open-access-imgOpen Access
Cost‐Effectiveness of Tenofovir as First‐Line Antiretroviral Therapy in India
Author(s) -
Melissa Bender,
Nagalingeswaran Kumarasamy,
Kenneth H. Mayer,
Bingxia Wang,
Rochelle P. Walensky,
Timothy P. Flanigan,
Bruce R. Schackman,
Callie A. Scott,
Zhigang Lu,
Kenneth A. Freedberg
Publication year - 2010
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/649884
Subject(s) - stavudine , zidovudine , lamivudine , medicine , tenofovir , reverse transcriptase inhibitor , nevirapine , abacavir , kharif crop , antiretroviral therapy , human immunodeficiency virus (hiv) , virology , viral load , viral disease , statistics , mathematics , virus , hepatitis b virus , field experiment
World Health Organization guidelines for antiretroviral treatment (ART) in resource-limited settings recommend either stavudine or tenofovir as part of initial therapy. We evaluated the clinical outcomes and cost-effectiveness of first-line ART using tenofovir in India, compared with current practice using stavudine or zidovudine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here